Ldl Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Low-Density Lipoprotein Receptor (LDLR) is a cell surface receptor responsible for the uptake of LDL cholesterol into cells. It plays a crucial role in maintaining plasma cholesterol homeostasis and is essential for preventing atherosclerotic cardiovascular disease. LDLR is expressed primarily in the liver but also in other tissues including the adrenal glands, ovaries, and brain. The receptor undergoes constitutive endocytosis and recycling, efficiently clearing circulating LDL particles and delivering cholesterol to cells for membrane synthesis, steroid hormone production, and bile acid formation.
| Attribute |
Value |
| Gene Symbol |
LDLR |
| Protein Name |
LDL Receptor |
| Molecular Weight |
~160 kDa (precursor), ~115 kDa (mature) |
| Structure |
839 amino acids |
| Aliases |
LDL-R, FH |
| UniProt ID |
P01130 |
| Tissue Expression |
Liver (highest), adrenal, ovary, brain |
The LDLR is a type I transmembrane glycoprotein with multiple functional domains:
¶ Extracellular Domain
- Ligand-Binding Repeats (7): Cys-rich repeats (A1-A7) that bind apolipoprotein B100
- EGF-Like Repeats (3): Required for pH-dependent release of LDL in endosomes
- Beta-Propeller Domain: Facilitates ligand release at low pH
¶ Transmembrane Domain
- Single-pass alpha-helical transmembrane segment (residues 696-718)
- Anchors receptor in plasma membrane
- NPXY Internalization Signal: Required for clathrin-mediated endocytosis
- Di-Leucine Motif: Additional sorting signal
- Phosphorylation Sites: Regulate interaction with endocytic proteins
¶ LDL Binding and Internalization
- LDLR binds LDL particles via apolipoprotein B100 (apoB100)
- Receptor-LDL complex internalizes via clathrin-coated pits
- Acidic environment in endosome causes LDL release
- LDLR recycles to cell surface; LDL proceeds to lysosomes
- Provides cholesterol for:
- Cell membrane synthesis
- Steroid hormone synthesis (adrenal, gonads)
- Bile acid synthesis (liver)
- Regulates cellular cholesterol through:
- HMG-CoA reductase inhibition (feedback)
- ACAT-mediated esterification
- Endoplasmic reticulum stress response
- PCSK9 binds LDLR and targets it for lysosomal degradation
- Prevents receptor recycling
- Reduces LDL clearance
- Therapeutic target: PCSK9 inhibitors (alirocumab, evolocumab)
| Factor |
Effect |
| Sterol Regulatory Element-Binding Protein (SREBP2) |
Upregulates expression |
| Statins |
Increase LDLR transcription |
| Insulin |
Complex regulation |
| Estrogen |
Upregulates hepatic LDLR |
- PCSK9-mediated degradation
- Proprotein convertase cleavage
- Receptor glycosylation
- Endocytic recycling rate
- Caused by LDLR mutations (autosomal dominant)
- Types:
- FH1: LDLR defects (85% of cases)
- FH2: APOB defects
- FH3: PCSK9 gain-of-function
- Phenotype: Elevated LDL-C, tendon xanthomas, premature CVD
- Heterozygotes: ~50% reduced clearance
- Homozygotes: Near-zero clearance (severe phenotype)
- LDLR dysfunction accelerates plaque formation
- LDLR knockout mice develop atherosclerosis
- Relationship with LDL-C levels is curvilinear
- Even modest LDLR reduction increases risk
- LDLR variants modulate AD risk
- LDLR affects amyloid-beta transport
- Potential role in cerebral amyloid angiopathy
- Brain LDLR regulates neuronal cholesterol
- LDLR affects Aβ clearance from brain
- Perivascular drainage pathway
- Interaction with APOE isoforms
- Target for therapeutic intervention
| Drug Class |
Example |
Mechanism |
| Statins |
Atorvastatin, Rosuvastatin |
SREBP2 activation, upregulate LDLR |
| PCSK9 mAbs |
Alirocumab, Evolocumab |
Prevent LDLR degradation |
| Bile Acid Sequestrants |
Colestipol |
Increase LDLR expression |
| PCSK9 siRNA |
Inclisiran |
Reduce PCSK9 production |
- Levanog (Glybera): First gene therapy approved (AAV-LDLR for FH)
- CRISPR-based approaches: In development
- AAV vectors: Target liver for LDLR expression
- Small molecules to stabilize LDLR
- Antisense oligonucleotides targeting PCSK9
- Gene editing (CRISPR/Cas9)
- Liver-specific targeting
| Partner |
Interaction |
Functional Consequence |
| APOB-100 |
Ligand binding |
LDL particle recognition |
| PCSK9 |
Binding/degradation |
Receptor downregulation |
| ARH |
Adaptor protein |
Clathrin-mediated endocytosis |
| Dab2 |
Adaptor protein |
LDLR internalization |
| Clathrin |
Endocytosis |
Coated pit formation |
- LDLR Knockout Mice: Elevated LDL-C, atherosclerosis on Western diet
- Transgenic LDLR: Rescue of hypercholesterolemia
- Humanized Mice: Express human LDLR for drug testing
- Understanding brain-specific LDLR functions
- LDLR-Aβ interactions in neurodegeneration
- Biomarker development
- Gene therapy optimization for CNS disorders
The study of Ldl Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Goldstein et al., 2009. LDL receptor and cholesterol homeostasis. Annu Rev Biochem. PMID:19300252
- Martins et al., 2009. LDLR and Alzheimer's disease. J Alzheimer's Dis. PMID:19221856
- Rader and Hovingh, 2014. Lipid disorders. N Engl J Med. PMID:25119611
- Brown and Goldstein, 1986. LDL receptor and FH. Science. PMID:3513324
- Horton et al., 2009. SREBPs and lipid synthesis. Cell. PMID:19663923
- Lambert et al., 2012. PCSK9 and LDLR. Nat Rev Cardiol. PMID:22968186
- Deane et al., 2013. LDLR and Aβ clearance. Nat Rev Neurol. PMID:23897173
- Go and Mani, 2012. LDLR gene therapy. Mol Ther. PMID:22334016
¶ Lipoprotein Binding and Internalization
The LDL receptor (LDLR) mediates cellular uptake of cholesterol:
- Binds apolipoprotein B-100 (apoB-100) on LDL particles
- Recognizes apoE-containing lipoproteins (VLDL, IDL)
- Clathrin-mediated endocytosis internalizes the receptor-ligand complex
- Acidic pH in endosomes triggers ligand release
- Receptor recycles to the cell surface
LDLR plays a central role in systemic cholesterol balance:
- Maintains plasma LDL levels
- Supplies cholesterol to peripheral tissues
- Regulates hepatic cholesterol content
- Impacts atherosclerotic cardiovascular disease risk
- LDLR mutations cause autosomal dominant FH
- Heterozygous prevalence: 1 in 250-500
- Elevated LDL cholesterol from birth
- Premature coronary artery disease
- Treatment: statins, PCSK9 inhibitors, LDL apheresis
- LDLR polymorphisms influence AD risk
- LDLR regulates brain cholesterol homeostasis
- Implicated in Aβ clearance across the BBB
- Connection to lipid metabolism in neurodegeneration
- LDLR variants associated with stroke risk
- Cholesterol-lowering reduces stroke incidence
- Cerebral small vessel disease connections
| Drug Class |
Mechanism |
Examples |
| Statins |
HMG-CoA reductase inhibition |
Atorvastatin, Rosuvastatin |
| PCSK9 inhibitors |
LDLR degradation prevention |
Alirocumab, Evolocumab |
| Bile acid sequestrants |
Cholesterol excretion |
Cholestyramine |
| LDL apheresis |
Direct LDL removal |
Weekly/biweekly |
- Gene therapy for LDLR deficiency
- Brain-specific LDLR modulation
- Understanding LDLR in CNS cholesterol transport
- LDLR and amyloid pathology interactions
- Goldstein JL, Brown MS. (2009). "The LDL receptor". Arteriosclerosis, Thrombosis, and Vascular Biology. PMID:19228604.
2.inner J, Toth PP, Watts GF, et al. (2020). "Familial hypercholesterolemia: JACC Focus Seminar". Journal of the American College of Cardiology. PMID:32819532.
- Kim J, Basak JM, Holtzman DM. (2009). "The role of apolipoprotein E in Alzheimer's disease". Neuron. PMID:19369327.
- Zhao L, Varghese M, Zong W, et al. (2011). "Recycling of apolipoprotein E and lipoproteins from brain". Neurobiology of Aging. PMID:20619503.
- Patel KM, Strong A, Tohyama J, et al. (2015). "Macrophage LDL receptor: role in atherosclerosis". Current Opinion in Lipidology. PMID:25831456.